AstraZeneca AZN shares are trading higher after the company announced lynparza PROpel trial met the primary endpoint in metastatic castration-resistant prostate cancer.
"We are encouraged by the PROpel results and the clinical benefit LYNPARZAin combination with abiraterone demonstrated versus abiraterone alone as a 1st-line treatment option for men with metastatic castration-resistant prostate cancer. Today's results build on Merck MRK and AstraZeneca's commitment to bring LYNPARZA earlier in lines of treatmentand to more patients with advanced prostate cancer," said Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, Merck.
The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology.
AstraZeneca has a 52-week high of $60.93 and a 52-week low of $46.48.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
